Stocktoria
Arcutis Biotherapeutics, Inc. ARQT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-01-31
Arcutis Biotherapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $376.1M | $196.5M | $59.6M | $3.7M | $0 |
| R&D expense | $77.1M | $76.4M | $110.6M | $182.4M | $145.6M |
| SG&A expense | $274.6M | $229.4M | $185.1M | $122.1M | $61.0M |
| Operating income | -$12.2M | -$128.4M | -$241.1M | -$301.6M | -$206.5M |
| Interest expense | — | — | $29.7M | $15.7M | $0 |
| Income tax | $1.2M | $647,000 | $3.1M | $0 | $0 |
| Net income | -$16.1M | -$140.0M | -$262.1M | -$311.5M | -$206.4M |
| EPS (diluted) | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.18 |
| Operating cash flow | -$5.6M | -$112.2M | -$247.1M | -$257.7M | -$174.6M |
| Free cash flow | -$6.3M | -$112.3M | -$247.5M | -$258.0M | -$175.6M |
| Cash & equivalents | $42.9M | $71.3M | $88.4M | $53.6M | $96.4M |
| Inventory | $22.6M | $14.5M | $13.1M | $7.5M | $0 |
| Total assets | $433.0M | $348.9M | $341.4M | $449.3M | $408.2M |
| Total liabilities | $243.5M | $191.3M | $252.7M | $239.7M | $110.5M |
| Shareholders' equity | $189.5M | $157.5M | $88.7M | $209.6M | $297.7M |
Source: SEC EDGAR filings · CIK 0001787306 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.